Overview
Chemed Q2 2025 revenue rises 3.8% but misses analyst expectations, per LSEG data
Adjusted EPS for Q2 2025 falls 21.9% and misses estimates, per LSEG data
Co announces departure of unit VITAS' CEO Nicholas M. Westfall, effective Dec 1, 2025
Outlook
Chemed revises 2025 EPS guidance to $22.00-$22.30, down from $24.95-$25.45
VITAS expects 2025 revenue to grow 7.5%-8.5% before Medicare Cap
Roto-Rooter forecasts 2025 revenue increase of 1.25%-1.75%
Chemed estimates $28.2 mln in 2025 Medicare Cap billing limitations
Result Drivers
VITAS REVENUE GROWTH - Driven by 6.1% increase in days-of-care and 4.2% rise in Medicare reimbursement rates
MEDICARE CAP IMPACT - Revenue growth negatively affected by Medicare Cap billing limitations, totaling $16.4 mln in Q2
ROTO-ROOTER SLUGGISH GROWTH - Revenue rose only 0.6% with declines in plumbing and drain cleaning services
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Revenue | Miss | $618.80 mln | $628.60 mln (4 Analysts) |
Q2 Adjusted EPS | Miss | $4.27 | $4.98 (3 Analysts) |
Q2 EPS | $3.57 | ||
Q2 Net Income | $52.49 mln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the healthcare facilities & services peer group is "buy"
Wall Street's median 12-month price target for Chemed Corp is $645.00, about 27.7% above its July 28 closing price of $466.08
The stock recently traded at 18 times the next 12-month earnings vs. a P/E of 24 three months ago
Press Release: ID:nBw6z9BKWa
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.